## Corporate Action Notice



November 23, 2010

Ratio Change

## RE: Clinuvel Pharmaceuticals Limited - Ratio Change

Clinuvel Pharmaceuticals Limited ("Clinuvel") (symbol:CLVLY) announced a reverse split on its ordinary shares in Australia of 1 new share for every 10 shares held. As a result of this reverse split in the local market, Clinuvel has instructed The Bank of New York Mellon, as Depositary to effect a ratio change on the ADR program as follows:

Clinuvel Pharmaceuticals Limited (CUSIP # 188769103)

Old Ratio - 1 American Depositary Share ("ADS"): 10 Ordinary Shares

New Ratio – 1 ADS : 1 Ordinary Share **Effective Date – November 26, 2010** 

No exchange of ADR certificates is required. Any outstanding ADR certificates will automatically be deemed to conform to the new parameters of the ADR facility. ADR holders need not take any action in regards to this ratio change.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York	London	Hong Kong
Jason Smith	Damon Rowan	Joe Oakenfold
Vice President	Vice President	Vice President
+1 212 815-3874	+44 207 964 6527	+852 2 840 9717
iason.smith@bnvmellon.com	damon.rowan@bnymellon.com	ioe.oakenfold@bnymellon.com

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.